Cronos Cannabis Company Slashes Losses, Reports Highest Quarterly Net Revenue In Q1 2024
Cronos Cannabis Company Slashes Losses, Reports Highest Quarterly Net Revenue In Q1 2024
Cronos Group Inc., (NASDAQ:CRON) a global cannabinoid company, has reported an increase in net revenue for the first quarter of 2024. The company's net revenue surged by 30%, reaching $25.3 million, driven primarily by sales in Canada and Israel.
全球大麻素公司克羅諾斯集團公司（納斯達克股票代碼：CRON）報告稱，2024年第一季度的淨收入有所增加。該公司的淨收入激增了30％，達到2530萬美元，這主要是由加拿大和以色列的銷售推動的。
Despite this revenue upswing, Cronos posted a net loss of $2.48 million for the quarter, an improvement from the $18.04 million loss reported in the same period last year.
儘管收入有所上升，但Cronos公佈的本季度淨虧損爲248萬美元，較去年同期公佈的1,804萬美元虧損有所改善。
Gross profits rose to $4.48 million, marking a 53% increase year-over-year with a rise in gross margin to 18%.
毛利潤增至448萬美元，同比增長53％，毛利率上升至18％。
Cronos's adjusted EBITDA, showing a reduction in losses, decreased to $10.67 million from $15.68 million in Q1 2023. This reduction reflects Cronos's cost-control measures and operational efficiencies implemented during the period.
克羅諾斯調整後的息稅折舊攤銷前利潤從2023年第一季度的1,568萬美元降至1,067萬美元，虧損有所減少。這一減少反映了Cronos在此期間實施的成本控制措施和運營效率。
Additionally, the company's balance sheet showed $855 million in cash and equivalents, positioning Cronos well for ongoing market expansion initiatives.
此外，該公司的資產負債表顯示8.55億美元的現金及等價物，使Cronos爲持續的市場擴張計劃做好了準備。
"Cronos achieved its highest quarterly net revenue from continuing operations on record at $25.3 million, up 30% year-over-year. The top line was propelled by 31% growth year-over-year in Canada, and 27% growth year-over-year in Israel. Cronos' strong first quarter results are a testament to our global team's commitment to excellence," said Mike Gorenstein, chairman, president and CEO of Cronos.
“Cronos實現了有記錄以來最高的持續經營業務季度淨收入，達到2530萬美元，同比增長30％。加拿大同比增長31％，以色列同比增長27％，推動收入增長。克羅諾斯第一季度強勁的業績證明了我們全球團隊對卓越的承諾。” Cronos董事長、總裁兼首席執行官邁克·戈倫斯坦說。
Deep Dive: YoY Performance
深度探討：同比表現
A deep dive into Cronos's financial data for the three months ended March 31, 2024, compared to the same period in 2023 reveals notable changes in various key metrics.
與2023年同期相比，對Cronos截至2024年3月31日的三個月的財務數據進行了深入研究，發現各種關鍵指標發生了顯著變化。
Consolidated net revenue increased by nearly $5.8 million, or 30%, while the cost of sales rose by $4,237,000, or 26%.
合併淨收入增長了近580萬美元，增長了30％，而銷售成本增加了423.7萬美元，增長了26％。
Furthermore, Cronos reported a significant positive swing in net income (loss), reaching ($2,484,000) in 2024 from ($18,035,000) in 2023, reflecting an 86% improvement.
此外，克羅諾斯報告稱，淨收益（虧損）出現了顯著的正向波動，從2023年的（18,035,000美元）達到2024年的2,484,000美元，反映了86％的增長。
Adjusted EBITDA increased by $5,013,000, or 32%, indicating enhanced operational performance.
調整後的息稅折舊攤銷前利潤增加了5,013,000美元，增長了32％，這表明運營業績有所提高。
While the increases in net revenue, gross profit and cash reserves suggest potential growth and financial stability, investors should note the persistent losses reflected in the net income (loss) figures.
儘管淨收入、毛利和現金儲備的增加表明了潛在的增長和財務穩定，但投資者應注意淨收益（虧損）數據中反映的持續虧損。
However, Cronos's ongoing strategic initiatives, including the introduction of the PEACE NATURALS brand in the UK and continued innovations across its Spinach and Lord Jones brands in Canada are expected to bolster market presence and contribute to long-term sustainable growth.
但是，克羅諾斯正在進行的戰略舉措，包括在英國推出PEACE NATURALS品牌以及在加拿大持續創新其菠菜和Lord Jones品牌，預計將增強市場佔有率並促進長期可持續增長。
Scanning through cannabis spreadsheets can take some time. To learn more about investing, don't miss the opportunity to join us at the 19th Benzinga Cannabis Capital Conference in Chicago this October 8-9. Engage with top executives, investors, policymakers, and advocates to explore the industry's future. Secure your tickets now before prices increase by following this link.
掃描大麻電子表格可能需要一些時間。要了解有關投資的更多信息，請不要錯過參加將於10月8日至9日在芝加哥舉行的第19屆Benzinga大麻資本會議的機會。與高層管理人員、投資者、政策制定者和倡導者互動，探索該行業的未來。在價格上漲之前，立即通過以下方式保護您的門票 這個鏈接。
Photo: AI-Generated Image.
照片：人工智能生成的圖像。
譯文內容由第三人軟體翻譯。